Intravitreal Aflibercept Injection for Radiation Retinopathy Trial
Status:
Active, not recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
The ARRT trial will assess the safety and efficacy of 2mg aflibercept for the treatment of
radiation retinopathy, including maculopathy and optic neuropathy over 52 weeks.